Michael A. Erb

Michael A. Erb

Auto-generated profile, based on publicly available information

Michael A. Erb

Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
BNBehnam Nabet
Behnam Nabet
JRJustin M. Roberts
Justin M. Roberts
DBDennis L. Buckley
Dennis L. Buckley
JPJoshiawa Paulk
Joshiawa Paulk
SDShiva Dastjerdi
Shiva Dastjerdi
JBJames E. Bradner
James E. Bradner

18 December 2017 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
COCalla M Olson
Calla M Olson
BJBaishan Jiang
Baishan Jiang
MEMichael A Erb
Michael A Erb
YLYanke Liang
Yanke Liang
ZDZainab M Doctor
Zainab M Doctor
NGNathanael S Gray
Nathanael S Gray

1 July 2017 in Molecular Cell
Verified
Journal Article
Closed access
GWGeorg E. Winter
Georg E. Winter
AMAndreas Mayer
Andreas Mayer
DBDennis L. Buckley
Dennis L. Buckley
MEMichael A. Erb
Michael A. Erb
JRJustine E. Roderick
Justine E. Roderick
JBJames E. Bradner
James E. Bradner

1 March 2017 in Nature
Verified
Journal Article
Open access
PDF file
MEMichael A. Erb
Michael A. Erb
TSThomas G. Scott
Thomas G. Scott
BLBin E. Li
Bin E. Li
HXHuafeng Xie
Huafeng Xie
JPJoshiawa Paulk
Joshiawa Paulk
JBJames E. Bradner
James E. Bradner
ENL, identified in a genome-scale loss-of-function screen as a crucial requirement for proliferation of acute leukaemia, is required for leukaemic gene expression, and its YEATS chromatin-reader domain is essential for leukaemic growth. Recurrent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene give rise to acute myeloid leukaemia (AML). Here, James Bradner and colleagues perform a genome-scale loss-of-function screen using CRISPR–Cas9 technology in MLL-AF4 AML cells. They find that the ENL gene is critical for cell proliferation and use a chemical genetic strategy of targeted protein degradation to show that loss of ENL suppresses transcriptional activation as well as leukaemic growth. ENL-dependent leukaemic growth depends on its YEATS chromatin reader domain, indicating that competitive antagonists of the YEATS domain could be potential therapeutics for AML. A related paper in this week's issue of Nature from Xiaobing Shi and colleagues provides insights into the function of the ENL YEATS domain in recognizing acetylated histones. Recurrent chromosomal translocations producing a chimaeric MLL oncogene give rise to a highly aggressive acute leukaemia associated with poor clinical outcome1. The preferential involvement of chromatin-associated factors as MLL fusion partners belies a dependency on transcription control2. Despite recent progress made in targeting chromatin regulators in cancer3, available therapies for this well-characterized disease remain inadequate, prompting the need to identify new targets for therapeutic intervention. Here, using unbiased CRISPR–Cas9 technology to perform a genome-scale loss-of-function screen in an MLL-AF4-positive acute leukaemia cell line, we identify ENL as an unrecognized gene that is specifically required for proliferation in vitro and in vivo. To explain the mechanistic role of ENL in leukaemia pathogenesis and dynamic transcription control, a chemical genetic strategy was developed to achieve targeted protein degradation. Acute loss of ENL suppressed the initiation and elongation of RNA polymerase II at active genes genome-wide, with pronounced effects at genes featuring a disproportionate ENL load. Notably, an intact YEATS chromatin-reader domain was essential for ENL-dependent leukaemic growth. Overall, these findings identify a dependency factor in acute leukaemia and suggest a mechanistic rationale for disrupting the YEATS domain in disease.

1 March 2017 in Nature
Verified
Journal Article
Open access
PDF file
LWLiling Wan
Liling Wan
HWHong Wen
Hong Wen
YLYuanyuan Li
Yuanyuan Li
LLLiyu Liu
Liyu Liu
YXYuanxin Xi
Yuanxin Xi
XSXiaobing Shi
Xiaobing Shi
The chromatin-reader protein ENL regulates oncogenic programs in acute myeloid leukaemia by binding via its YEATS domain to acetylated histones on the promoters of actively transcribed genes and recruiting the transcriptional machinery. Cancer cells often exploit transcription machinery and chromatin regulatory pathways to activate oncogenic gene expression programs. Chromatin regulatory mechanisms such as the recognition of modified histones by 'reader' proteins are therefore being explored as potential therapeutic targets in cancer. Here, Xiaobing Shi and colleagues show that ENL is a chromatin reader protein that regulates oncogenic programs in acute myeloid leukaemia (AML). It binds via its YEATS domain to acetylated histones on the promoters of actively transcribed genes and links to the transcriptional machinery. Depletion of ENL leads to anti-leukaemic effects, indicating that disrupting the interaction between the ENL YEATS domain and acetylated histones could be a potential therapeutic approach for AML, either alone or in combination with BET inhibitors. A related paper in this week's issue of Nature from James Bradner and colleagues provides further insights into the role of ENL in leukaemia. Cancer cells are characterized by aberrant epigenetic landscapes and often exploit chromatin machinery to activate oncogenic gene expression programs1. Recognition of modified histones by ‘reader’ proteins constitutes a key mechanism underlying these processes; therefore, targeting such pathways holds clinical promise, as exemplified by the development of bromodomain and extra-terminal (BET) inhibitors2,3. We recently identified the YEATS domain as an acetyl-lysine-binding module4, but its functional importance in human cancer remains unknown. Here we show that the YEATS domain-containing protein ENL, but not its paralogue AF9, is required for disease maintenance in acute myeloid leukaemia. CRISPR–Cas9-mediated depletion of ENL led to anti-leukaemic effects, including increased terminal myeloid differentiation and suppression of leukaemia growth in vitro and in vivo. Biochemical and crystal structural studies and chromatin-immunoprecipitation followed by sequencing analyses revealed that ENL binds to acetylated histone H3, and co-localizes with H3K27ac and H3K9ac on the promoters of actively transcribed genes that are essential for leukaemia. Disrupting the interaction between the YEATS domain and histone acetylation via structure-based mutagenesis reduced the recruitment of RNA polymerase II to ENL-target genes, leading to the suppression of oncogenic gene expression programs. Notably, disrupting the functionality of ENL further sensitized leukaemia cells to BET inhibitors. Together, our data identify ENL as a histone acetylation reader that regulates oncogenic transcriptional programs in acute myeloid leukaemia, and suggest that displacement of ENL from chromatin may be a promising epigenetic therapy, alone or in combination with BET inhibitors, for aggressive leukaemia.

29 January 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RZRhamy Zeid
Rhamy Zeid
MLMatthew A. Lawlor
Matthew A. Lawlor
EPEvon Poon
Evon Poon
JRJaime M. Reyes
Jaime M. Reyes
MFMariateresa Fulciniti
Mariateresa Fulciniti
JBJames E. Bradner
James E. Bradner